Cost–utility analysis of trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer in Chinese setting

被引：0
|
作者：
Shanshan Hu
Yilai Wu
Jiajie Luan
Shuowen Wang
Guorong Fan
机构：
[1] Shanghai General Hospital,Department of Clinical Pharmacy
[2] Shanghai Jiao Tong University School of Medicine,Department of Pharmacy
[3] The First Affiliated Hospital of Wannan Medical College,undefined
来源：
Journal of Cancer Research and Clinical Oncology | 2023年 / 149卷
关键词：
Cost–utility analysis; HER2-positive metastatic breast; Trastuzumab deruxtecan; Trastuzumab emtansine; Price exploring;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：17933 / 17942
页数：9
相关论文
共 50 条
  • [41] Cost-Effectiveness Analysis of Trastuzumab Deruxtecan versus Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer in the USA
    Jingyan Wang
    Yinzhi Yi
    Xiaomin Wan
    Xiaohui Zeng
    Ye Peng
    Chongqing Tan
    Advances in Therapy, 2022, 39 : 4583 - 4593
  • [42] Trastuzumab deruxtecan versus trastuzumab emtansine for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: A cost-effectiveness analysis
    Zhu, Youwen
    Liu, Kun
    Wang, Min
    Wang, Kailing
    Zhu, Hong
    BREAST, 2022, 66 : 191 - 198
  • [43] Cost-Effectiveness Analysis of Trastuzumab Deruxtecan versus Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer in the USA
    Wang, Jingyan
    Yi, Yinzhi
    Wan, Xiaomin
    Zeng, Xiaohui
    Peng, Ye
    Tan, Chongqing
    ADVANCES IN THERAPY, 2022, 39 (10) : 4583 - 4593
  • [44] Trastuzumab emtansine in HER2-positive metastatic breast cancer: pooled safety analysis from seven studies
    Dieras, V.
    Harbeck, N.
    Budd, G. T.
    Greenson, J. K.
    Guardino, E.
    Samant, M.
    Chernyukhin, N.
    Smitt, M.
    Krop, I. E.
    CANCER RESEARCH, 2012, 72
  • [45] Trastuzumab emtansine in HER2-positive metastatic breast cancer after pertuzumab and trastuzumab: TDM1RM Study
    Martinez-Garcia, J.
    Puertes Boix, A.
    Sanchez Henarejos, P.
    Jimenez Lucas, M. D.
    Sanchez Saura, A.
    Luengo, M.
    Carrillo Vicente, R.
    Martinez Ortiz, M. J.
    Balsalobre, J.
    de la Morena Barrio, P. D. L. M.
    Garcia Garre, E.
    Garcia, E.
    Marin, G.
    Garcia Torralba, E.
    Ayala de la Pena, F.
    Collado, D.
    Lopez, A.
    Quiros, T.
    Sanchez, D. A.
    Romero, J. L. A.
    ANNALS OF ONCOLOGY, 2020, 31 : S358 - S358
  • [46] Trastuzumab deruxtecan for HER2-positive metastatic breast cancer: DESTINY-Breast01 subgroup analysis.
    Modi, Shanu
    Andre, Fabrice
    Krop, Ian E.
    Saura, Cristina
    Yamashita, Toshinari
    Kim, Sung-Bae
    Tamura, Kenji
    Chen, Shuquan
    Suto, Fumitaka
    Kuwahara, Yusuke
    Lee, Caleb C.
    Park, Yeon Hee
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [47] Trastuzumab deruxtecan in the treatment of adult patients with HER2-positive breast cancer
    Kufel-Grabowska, Joanna
    ONCOLOGY IN CLINICAL PRACTICE, 2023, 19 (05): : 377 - 381
  • [48] Development of trastuzumab emtansine (Kadcyla®) for thetreatment of HER2-positive breast cancer
    Phillips, Gail
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2015, 250
  • [49] Profiling and targeting HER2-positive breast cancer using trastuzumab emtansine
    Sadeghi, Saeed
    Olevsky, Olga
    Hurvitz, Sara A.
    PHARMACOGENOMICS & PERSONALIZED MEDICINE, 2014, 7 : 329 - 338
  • [50] Trastuzumab emtansine: a game changer in HER2-positive early breast cancer
    Mano, Max S.
    FUTURE ONCOLOGY, 2020, 16 (32) : 2595 - 2609
12345